EPCORE™ FL-1

M20-638

Don't face the journey with lymphoma *alone*.

The journey with follicular lymphoma shouldn't be a lonely one—join a growing community of people seeking answers through clinical research. Consider participating in the EPCORE FL-1 clinical research study.

The EPCORE FL-1 Clinical Research Study

The EPCORE FL-1 Study is evaluating the safety and effectiveness of an investigational drug in combination with standard-of-care drugs for adults with relapsed or refractory follicular lymphoma.

You may be able to take part in the EPCORE FL-1 Study if you:

- Are at least 18 years old
- Have a diagnosis of relapsed or refractory follicular lymphoma (Stage 2, 3, or 4)
  - Relapsed: Your lymphoma previously responded to therapy but progressed 6 months or later after completing therapy
  - Refractory: Your lymphoma either progressed during therapy, did not respond to prior therapy, or progressed within 6 months after completing therapy (including maintenance therapy)

If you are interested in participating, the study doctor and staff will review additional eligibility criteria with you.

This investigational drug being studied in FL patients is under clinical development and is not approved for use by regulatory health authorities. Safety and effectiveness are under evaluation.

FAQs

What's involved with participation in the EPCORE FL-1 Study?

Participants will receive the investigational drug along with standard-of-care drug regimens, or the standard-of-care drugs alone, while completing various study tests and procedures.

- The study duration will vary from person to person depending on their response to their assigned study drugs.
- Each study drug cycle will last 28 days.
  - Participants and the study staff will know which study drug or drugs are being given. There is no placebo in this study, which means all participants will receive study treatment.
- The investigational drug will be given as a subcutaneous injection (under the skin). One standard-of-care drug will be given through an intravenous injection (delivered through a tiny tube into the vein) and the other standard-of-care drug is a capsule or tablet that will be taken by mouth.
- Participants may leave the study at any point in time.

Does participating in this study cost anything?

If you qualify for and agree to participate in the study, you will not have to pay for the investigational drug. In addition, reimbursement for study-related travel expenses may be available.

If prequalified, what can I expect on my first visit to the study clinic?

This initial appointment is an opportunity for you to:

- **Ask any important questions you may have.** These can be any questions you may have about this study or clinical research in general.
- **Determine if the EPCORE FL-1 Study may be right for you.** You will speak with a study coordinator and learn more about the study. The study coordinator will ask you about your health history to determine if you are eligible for the study. If you are eligible, you will be given the opportunity to decide if participation is right for you. If you agree to take part, you will be asked to review and sign a consent form for study participation. You can also leave the study at any time. Once you have signed the study consent form, the research staff will perform a series of tests to determine if you are right for the study, and if the study is right for you.

What if my condition worsens or I have side effects?

You should make sure to inform your doctor of any new symptoms you experience while participating in the study. If you experience worsening of your disease at any time during the study, please let the study doctor and staff know.

Where are the study clinics located?

There are study clinics located throughout the world. Find a location near you at **EPCORE-trials.com/locations**.